...
GMABLARGE

Genmab A/S

HealthcareBiotechnology
$29.44
$0.00(+0.68%)
52W$17.24
$35.43
FinancialsValuationvs RVMD
Updated Mar 2, 12:00 AM
RSI38
RS Rating58/99
Beta0.61
Volatility37%
F-Score5/9
Mkt Cap$18.1B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Genmab A/S shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is moderate (RS Rating: 58), indicating performance broadly in line with the market. Earnings contraction of 67% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
58
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.61
vs S&P 500
DEFENSIVE
52W Position
67%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$32.00
50 SMA > 100 SMA$31.40
100 SMA > 150 SMA$29.60
150 SMA > 200 SMA$27.55

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$30.45-3.30%BELOW
50 SMA$32.00-8.01%BELOW
100 SMA$31.40-6.25%BELOW
150 SMA$29.60-0.55%BELOW
200 SMA$27.55+6.85%ABOVE

Price Performance

1D+0.7%
1W+0.6%
1M-10.6%
3M-9.0%
6M+17.2%
YTD-7.5%
1Y+29.8%
3Y-7.8%
52-Week Trading Range67% from low
$29.44
52W Low$17.24
52W High$35.43

Technical Indicators

RSI (14)BEARISH
38.3
305070
VCP ScoreCOOL
4/10
Base depth: 25.0%

Risk Profile

Beta
0.61
52W Vol
37%
ATR
$0.86
Max DD (1Y)
-26%

Volume Analysis

Today
29
50D Avg
1.48M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24+518%
$5.99
Q1'25-85%
$0.31
Q2'25+58%
$3.42
Q3'25-67%
$0.65
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+38.14%
5 Years:+32.03%
3 Years:+36.75%
TTM:+21.03%

Compounded Profit Growth

10 Years:+36.77%
5 Years:+28.99%
3 Years:+39.42%
TTM:+45.85%

Stock Price CAGR

10 Years:+9.08%
5 Years:-3.47%
3 Years:-7.80%
1 Year:+29.81%

Return on Equity

10Y Avg:21.9%
5Y Avg:20.6%
3Y Avg:19.9%
Last Year:114.2%

Key Metrics

Market Cap$18.1B
Gross Margin95.4%
Net Margin36.4%
Piotroski F-Score5/9

More GMAB Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

GMAB vs RVMDRVMDINCYEXELIBRX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 58 meansGMAB outperformed 58% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.61 means 39% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is GMAB in an uptrend right now?

GMAB has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is GMAB overbought or oversold?

GMAB's RSI (14) is 38. The stock is in neutral territory, neither overbought nor oversold.

Is GMAB outperforming the market?

GMAB has a Relative Strength (RS) Rating of 58 out of 99. GMAB is performing about average compared to the market.

Where is GMAB in its 52-week range?

GMAB is trading at $29.44, which is 83% of its 52-week high ($35.43) and 67% above its 52-week low ($17.24).

How volatile is GMAB?

GMAB has a Beta of 0.61 and 52-week volatility of 37%. It's less volatile than the S&P 500 - generally more stable.